主页 > 医学文档 >
【drug-news】疟疾疫苗在加纳开始临床试验
Start Of A Malaria Vaccine Trial In Ghana
The Bernhard Nocht Institute´s Ghanaian research centre KCCR is part of a multinational partnership conducting Phase II field trials for a new malaria vaccine candidate launched recently.
Malaria is a major cause of death for children in sub-Sahara Africa. The field trials in eight African study centres assess the immunological impact and safety of a promising malaria vaccine candidate.
The Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR) is a joint venture of the Hamburg-based Bernhard Nocht Institute for Tropical Medicine (BNITM) and the University of Science and Technology in Kumasi. "Being appointed as a study site in this partneship is a milestone for Kumasi´s recognition as an international research platform," says Rolf Horstmann, co-ordinator for research in the tropics at BNITM.
Pediatrician Dr. Jennifer Evans of BNITM and Prof. Tsiri Agbenyega, Dean of the School of Medical Sciences in Kumasi are the principal investigators at KCCR, which is one of two Ghanaian study sites. The study sites have recruited a total of 540 children ages 5-17 months to participate under close medical monitoring. "We will be examining different formulations and schedules for vaccination to see how these factors may influence outcomes" Dr. Evans states. "The studies are a critical step in making a malaria vaccine a reality for the people in Ghana and sub-Saharan Africa. The results of previous studies were already very encouraging."
However, patience is needed. If all goes well the vaccine could be submitted to regulatory authorities as early as 2010. The vaccine does not prevent all vaccinees from becoming infected with malaria parasites, but it does help to reduce the number of clinical episodes of malaria and the risk of developing severe malaria disease. Worldwide, an estimated 1,000,000 people die of malaria annually, most of them children below five years of age.
The vaccine named RTS,S was developed by GlaxoSmithKline Biologicals and partners in the US beginning in the late 1980s. Pilot studies conducted in adults showed its protective potential against Plasmodium falciparum, the pathogen causing the most severe form of malaria. Subsequently the vaccine was developed for infants and young children in co-operation with the PATH Malaria Vaccine Initiative, a programme largely financed by the Bill and Melinda Gates Foundation.
BNI would like to acknowledge its esteemed Ghanaian partners:
- Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana
- School of Medical Sciences (SMS), College of Health Sciences of KNUST
- Presbyterian Health Service Agogo, Ghana
- Kintampo Health Research Centre
- Ministry of Health of the Republic of Ghana 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Start Of A Malaria Vaccine Trial In Ghana
疫苗在加纳开始临床试验
The Bernhard Nocht Institute´s Ghanaian research centre KCCR is part of a multinational partnership conducting Phase II field trials for a new malaria vaccine candidate launched recently.
Bernhard Nocht学会的加纳研究中心KCCR是新近开始的一项新的疟疾疫苗二期地区试验的跨国合作伙伴之一。
Malaria is a major cause of death for children in sub-Sahara Africa. The field trials in eight African study centres assess the immunological impact and safety of a promising malaria vaccine candidate.
疟疾是非洲撒哈拉沙漠地区儿童最主要的死因之一。地区试验在八个非洲研究中心进行，以评估这个有前途的疟疾疫苗在免疫学和安全性方面的影响。
The Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR) is a joint venture of the Hamburg-based Bernhard Nocht Institute for Tropical Medicine (BNITM) and the University of Science and Technology in Kumasi. "Being appointed as a study site in this partneship is a milestone for Kumasi´s recognition as an international research platform," says Rolf Horstmann, co-ordinator for research in the tropics at BNITM.
库马西热带医学合作研究中心（KCCR）是由汉堡Bernhard Nocht热带医学学会（BNITM）和库马西科学技术大学合办的。“被指定为这项合作的研究站点对于库西马来说是一个里程碑，我们作为一个国际研究平台的地位被认可了。” Rolf Horstmann说，他是BNITM热带地区的研究协调员。
Pediatrician Dr. Jennifer Evans of BNITM and Prof. Tsiri Agbenyega, Dean of the School of Medical Sciences in Kumasi are the principal investigators at KCCR, which is one of two Ghanaian study sites. The study sites have recruited a total of 540 children ages 5-17 months to participate under close medical monitoring. "We will be examining different formulations and schedules for vaccination to see how these factors may influence outcomes" Dr. Evans states. "The studies are a critical step in making a malaria vaccine a reality for the people in Ghana and sub-Saharan Africa. The results of previous studies were already very encouraging."
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-09 17:29
医学,生命科学网